Fatty Acid Derivatives and Their Use for the Treatment and Prevention of Autoimmune, Inflammatory, and Pain Disorders

National Cancer Institute Background
The discovery and selection of suitable compounds for the treatment and prevention of autoimmune, inflammatory, and pain disorders is a significant challenge.
Technology Overview
Researchers at National Institute of Aging (NIA) mitigated this issue. They discovered and synthesized numerous novel fatty acid derivatives (novel small molecules) that may ameliorate these conditions and provide treatment options for these disorders. In a relevant rat model, the fatty acid derivatives developed by NIA demonstrated:

increased activity
lower toxicity
greater stability
longer half-life

These beneficial results favorably compare to prior agents utilized for treating inflammation, autoimmune disorders, and/or pain. Certain of the disclosed fatty acid derivatives are capable of readily crossing the blood-brain barrier – providing an advantage specifically with respect to certain pain disorders.
Further Details:
Ramden et al. A systems approach for discovering linoleic acid derivatives that potentially mediate pain and itch. [PMID: 28831021]
Stage of Development

Pre-clinical (in vivo)


Ability to readily cross the blood-brain barrier
Increased activity, lower toxicity, greater stability, and longer half-life in a relevant proof-of-concept rat model compared with drugs currently available for treating inflammation, autoimmune disorders, and/or pain
Substantial intellectual property life cycle: e.g., patents if issued likely will expire no earlier than 2038
Proof-of-concept in rat model


Autoimmune disorders
Pain-related disorders
Itching and/or skin disorders

NIA is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize fatty acid derivatives. In addition, NIA is open to collaborative research relationships (such as under a CRADA) whereby resources such as intellectual property can be pooled and applied to the development of therapies with respect to a wide variety of autoimmune and inflammatory and pain-related conditions. In addition, NIA is open to a wide variety of licensing arrangements with respect to these technologies.

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More